Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | XIAP | P98170 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821878 | 0.81 | NCF1 (0.46) | KDM4EGPR3ELANELRRK2ALDH1A1 | |
| SCHEMBL23447177 | 0.80 | KDM4E (0.44) | KDM4EGPR3HRH3ALDH1A1GAA | |
| SCHEMBL15414339 | 0.79 | KDM4E (0.42) | KDM4EGPR3HRH3ALDH1A1GAA | |
| SCHEMBL27668262 | 0.78 | LRRK2 (0.57) | KDM4EGPR3ELANELRRK2ALDH1A1 | |
| SCHEMBL4826614 | 0.75 | CYP1A2 (0.47) | ELANEALDH1A1HPGD | |
| SCHEMBL25820098 | 0.75 | IP6K1 (0.41) | ELANEALDH1A1HSD17B10 | |
| SCHEMBL26499887 | 0.75 | GAA (0.40) | KDM4EGPR3HRH3ALDH1A1GAA | |
| SCHEMBL10015631 | 0.73 | KDM4E (0.44) | KDM4EGPR3LRRK2 | |
| SCHEMBL25820158 | 0.72 | GPR3 (0.48) | KDM4EGPR3ELANEALDH1A1GAA | |
| SCHEMBL3156746 | 0.71 | CCR1 (0.52) | KDM4EGPR3HRH3TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDM4E 4095/4885GPR3 428/4885ELANE 1623/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | KDM4E 4219/4885GPR3 485/4885ELANE 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.